Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Creatine may increase DHT levels, potentially causing symptoms like acne, oily hair, and hair shedding. Users report mixed experiences, with some avoiding creatine due to hair loss concerns and others seeing no impact.

The conversation discusses struggles with diffuse thinning and hair loss treatments, including the use of dutasteride, minoxidil, and finasteride, with limited success. The original poster regrets having a hair transplant at 21 due to weak donor hair and ongoing thinning.

Finasteride prescriptions in France now require an annual certificate acknowledging psychiatric and sexual risks, as the European Medicines Agency recognizes these risks. The conversation discusses the potential mental health effects of Finasteride, with some users reporting side effects and others questioning the statistical significance of these findings.

The conversation discusses potential hair loss treatments, including clascoterone, GT20029, ET-02, VDPHL01, and PP405, with hopes for new options by 2028. Current treatments like minoxidil and finasteride are expected to remain effective, with clascoterone and VDPHL01 as promising alternatives.

The user experiences severe side effects from finasteride and dutasteride, including low libido and anxiety, and is currently using oral minoxidil despite shortness of breath. They are seeking alternative treatments for hair loss, having tried pyrilutamide, fluridil, and RU58841 with no success, and are considering future treatments or a hair transplant.

The conversation discusses a topical finasteride therapy with hydrocortisone butyrate, estrone base, and breviline. A user suggests oral finasteride as a superior option.

The user underwent a DHI hair transplant with 3,066 grafts at Hairtec in the Netherlands and is using finasteride and minoxidil to restore hair, particularly at the crown. They plan to adjust minoxidil dosage and consult with a dermatologist in September.

PP405 shows promise in hair regrowth, with 31% of participants experiencing over 20% increase in hair density after 8 weeks. Phase 3 trials are expected in 2026, with potential market availability by 2029-2031.

The conversation discusses using cyproterone temporarily to reverse hair loss, followed by finasteride to maintain regrowth. Concerns about cyproterone's side effects, such as lowering testosterone and potential health risks, are raised, with alternatives like spironolactone suggested for androgen-related issues.

A fake hair loss product called "PP405" is being humorously discussed, with users joking about its effectiveness and availability on resale websites. The consensus is that it's a scam, with some users sarcastically claiming miraculous results.

A user is curious why their DHT levels are not higher despite using 400mg of testosterone without finasteride, and wonders if zinc or GHK-Cu injections could be influencing this. Another user suggests that more testosterone typically leads to more DHT, but the user might be fortunate not to exceed normal DHT levels.

High dose topical Finasteride solutions are speculative and not proven more effective than low dose solutions. Users report varying results with different concentrations, with some preferring lower doses to minimize side effects.

PP405 shows promise as a hair loss treatment, with 31% experiencing increased hair density in a short trial. It may complement treatments like finasteride and minoxidil, but long-term effectiveness and safety need confirmation.

Dutasteride can be obtained more affordably through Amazon's RxPass program or telehealth services like Dr. B, with some users also mentioning options like Cost Plus Drugs and Miiskin for prescriptions. Users discuss switching from finasteride to dutasteride and mention additional treatments like minoxidil.

PP405 is still undergoing trials despite skepticism about its effectiveness. Some believe it shows potential for hair regrowth, possibly in combination with other treatments like minoxidil or finasteride, while others are doubtful due to past disappointments with similar products.

Post Finasteride Syndrome (PFS) is debated, with some users reporting severe side effects from finasteride, while others believe these effects are rare or psychosomatic. Treatments discussed include finasteride, minoxidil, and RU58841.

A user is considering dutasteride mesotherapy for hair loss due to concerns about oral side effects from high DHT levels. They have been using topical finasteride with minoxidil but are exploring mesotherapy as an alternative, while another user shares their experience with mesotherapy sessions using dutasteride and minoxidil without side effects.

The conversation is about a user's one-year hair loss treatment using dutasteride, oral and topical minoxidil, ketoconazole, tretinoin, and PRP. Users discuss treatment effectiveness, potential issues with diffuse thinning, and sourcing affordable treatments.

The conversation discusses using homemade topical finasteride for hair loss, showing an increase in DHT levels despite treatment. The user applies 0.125mg daily, resulting in 113.4% of previous DHT levels.

PP405 is considered a promising potential cure for hair loss, with phase 2 trial results expected in February 2025. Hair cloning is also discussed as a potential ultimate solution, despite significant scientific challenges.

The user has been using finasteride and minoxidil for 5 years with initial success but is now experiencing hair thinning despite increasing dutasteride usage. They are considering adjusting dutasteride frequency and possibly adding treatments like eucapil, minoxidil, and GHK-Cu peptides.

Pelage executives' hairlines were discussed, with speculation about them using PP405 for hair regrowth. Concerns were raised about using untested drugs, with some suggesting executives might not risk using them without safety data.

Some people have side effects from finasteride and dutasteride due to hormonal predisposition, especially if DHT dominant. Alternatives like RU58841, Pyrilutamide, and Breezula are suggested to target scalp androgen receptors without altering overall hormones.

The user has been using oral Dutasteride, RU58841, and Minoxidil for three years without success and is considering adding topical Finasteride or Dutasteride to target DHT both locally and systemically. Other users suggest sticking to a consistent treatment plan, exploring different combinations, and considering other factors like potential misdiagnosis or inconsistent medication use.

Pelage Pharmaceuticals is developing PP405, a topical treatment for hair growth, currently in Phase 2a trials. There is skepticism about the company's claims, and no fast-tracking approval timeline has been detailed.

A new hair loss treatment, pp405, may regrow hair better than finasteride and minoxidil, with potential availability by 2028. However, there is skepticism about its effectiveness and commercialization timeline.

The conversation discusses the potential availability and use of the pp405 molecule for hair loss treatment, with concerns about its legitimacy and safety on the grey market. Participants also mention using products from Umbrella Labs and discuss the concentration and production costs of pp405.

The user has been on dutasteride for 20 months with worsening hair loss and is considering switching back to finasteride, which previously stabilized their hair. They are using a regimen including dutasteride, oral and topical minoxidil, vitamins, and ketoconazole shampoo, and are planning to add microneedling.

The conversation discusses using minoxidil, finasteride, spironolactone, and RU58841 for hair loss treatment. Users share experiences with these treatments, noting side effects and varying effectiveness.

Topical Dutasteride, especially in a liposomal base, is recommended for enhanced scalp DHT suppression when used with oral Dutasteride. It is suggested to apply it twice a week for effective results without significant systemic impact.